{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:14:55Z","timestamp":1775214895808,"version":"3.50.1"},"reference-count":117,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Multiple myeloma is a clonal plasma cell malignancy with a highly variable range of clinical manifestations. Over recent decades, substantial progress has been made in laboratory diagnostics, which has deepened our understanding of disease biology, improved risk stratification, and informed treatment strategies. In an era of transformation and innovation, conventional laboratory methods remain essential, as cutting-edge technologies might not be immediately accessible to all laboratories. Nonetheless, even widely used laboratory methodologies present many challenges, such as variability in assay performance, interpretative criteria, and standardization. This review by the Portuguese Multiple Myeloma Group of the Portuguese Society of Hematology provides a comprehensive overview and practical appraisal of current conventional laboratory methods employed for multiple myeloma diagnosis.<\/jats:p>","DOI":"10.3390\/jcm14197115","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:47:08Z","timestamp":1760104028000},"page":"7115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9011-5818","authenticated-orcid":false,"given":"Ana Marta","family":"Pires","sequence":"first","affiliation":[{"name":"Clinical Pathology Department, Unidade Local de Sa\u00fade Tr\u00e1s-os-Montes e Alto Douro, 5000-508 Vila Real, Portugal"}]},{"given":"Jo\u00e3o Pedro","family":"Barreto","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7509-9066","authenticated-orcid":false,"given":"Joana","family":"Caetano","sequence":"additional","affiliation":[{"name":"Hemato-Oncology Unit, Funda\u00e7\u00e3o Champalimaud, 1400-038 Lisbon, Portugal"},{"name":"NOVA Medical School, NOVA University of Lisbon, 1169-056 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2766-3766","authenticated-orcid":false,"given":"Maria Jos\u00e9","family":"Soares","sequence":"additional","affiliation":[{"name":"Hematology Department, Unidade Local de Sa\u00fade S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"given":"Catarina","family":"Geraldes","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Unidade Local de Sa\u00fade de Coimbra, 3004-561 Coimbra, Portugal"},{"name":"Oncobiology and Hematology Laboratory, Faculdade de Medicina, Universidade de Coimbra, 3004-504 Coimbra, Portugal"},{"name":"Centro Acad\u00e9mico Cl\u00ednico de Coimbra, 3004-504 Coimbra, Portugal"}]},{"given":"Bruno","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}]},{"given":"Margarida","family":"Coucelo","sequence":"additional","affiliation":[{"name":"Molecular Hematology Laboratory, Clinical Hematology Service, Unidade Local de Sa\u00fade de Coimbra, 3004-561 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6316-8789","authenticated-orcid":false,"given":"S\u00e9rgio","family":"Chacim","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Service, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0909-9601","authenticated-orcid":false,"given":"Henrique","family":"Coelho","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Unidade Local de Sa\u00fade Gaia e Espinho, 4434-502 Vila Nova de Gaia, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-7756","authenticated-orcid":false,"given":"Cec\u00edlia","family":"Correia","sequence":"additional","affiliation":[{"name":"Laboratorial Genetics Department, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}]},{"given":"Ana Paula","family":"Cruz","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Unidade Local de Sa\u00fade Gaia e Espinho, 4434-502 Vila Nova de Gaia, Portugal"}]},{"given":"Manuel","family":"Cunha","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Unidade Local de Sa\u00fade Tr\u00e1s-os-Montes e Alto Douro, 5000-508 Vila Real, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9609-8935","authenticated-orcid":false,"given":"Maria Ros\u00e1rio","family":"Cunha","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Unidade Local de Sa\u00fade de Coimbra, 3004-561 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0726-7843","authenticated-orcid":false,"given":"Nuno","family":"Cunha","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Instituto Portugu\u00eas de Oncologia de Coimbra Francisco Gentil, 3000-075 Coimbra, Portugal"}]},{"given":"Patr\u00edcia","family":"Ferraz","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Unidade Local de Sa\u00fade Tr\u00e1s-os-Montes e Alto Douro, 5000-508 Vila Real, Portugal"}]},{"given":"Jos\u00e9 Guilherme","family":"Freitas","sequence":"additional","affiliation":[{"name":"Hematology Department, Unidade Local de Sa\u00fade de Braga, 4710-243 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Pathological Anatomy Department & Cancer Epigenetics and Biology Group, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"},{"name":"Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC) & RISE@CI-IPOP (Health Research Network), 4200-072 Porto, Portugal"},{"name":"Abel Salazar Biomedical Sciences Institute, Universidade do Porto, 4050-313 Porto, Portugal"}]},{"given":"Susana","family":"Lisboa","sequence":"additional","affiliation":[{"name":"Laboratorial Genetics Department, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}]},{"given":"Paulo","family":"L\u00facio","sequence":"additional","affiliation":[{"name":"Hemato-Oncology Unit, Funda\u00e7\u00e3o Champalimaud, 1400-038 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-5859","authenticated-orcid":false,"given":"Artur","family":"Paiva","sequence":"additional","affiliation":[{"name":"Operational Management Unit in Cytometry, Unidade Local de Sa\u00fade de Coimbra, 3004-561 Coimbra, Portugal"},{"name":"Coimbra Clinical and Biomedical Investigation Institute (iCBR), Faculdade de Medicina, Universidade do Coimbra, 3004-504 Coimbra, Portugal"},{"name":"Laborat\u00f3rio de Ci\u00eancias Biom\u00e9dicas, Escola Superior de Tecnologia da Sa\u00fade de Coimbra, Polytechnic Institute of Coimbra, 3045-093 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6566-0315","authenticated-orcid":false,"given":"Cl\u00e1udia","family":"Pedrosa","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Unidade Local de Sa\u00fade Santo Ant\u00f3nio, 4050-011 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6688-7466","authenticated-orcid":false,"given":"In\u00eas","family":"Ramos","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Service, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-4841","authenticated-orcid":false,"given":"Ana Bela","family":"Sarmento-Ribeiro","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Unidade Local de Sa\u00fade de Coimbra, 3004-561 Coimbra, Portugal"},{"name":"Oncobiology and Hematology Laboratory, Faculdade de Medicina, Universidade de Coimbra, 3004-504 Coimbra, Portugal"},{"name":"Centro Acad\u00e9mico Cl\u00ednico de Coimbra, 3004-504 Coimbra, Portugal"}]},{"given":"Patr\u00edcia","family":"Seabra","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Unidade Local de Sa\u00fade Santo Ant\u00f3nio, 4050-011 Porto, Portugal"}]},{"given":"Joana","family":"Sevilha","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade M\u00e9dio Ave, 4780-371 Santo Tirso, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-815X","authenticated-orcid":false,"given":"Maria Jos\u00e9 Rego de","family":"Sousa","sequence":"additional","affiliation":[{"name":"NOVA Medical School, NOVA University of Lisbon, 1169-056 Lisbon, Portugal"},{"name":"Germano de Sousa Clinical Laboratory Center, 1600-513 Lisbon, Portugal"},{"name":"Faculdade de Medicina, Universidade Cat\u00f3lica de Portugal, 1649-023 Lisbon, Portugal"}]},{"given":"Sara","family":"Sousa","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Unidade Local de Sa\u00fade Tr\u00e1s-os-Montes e Alto Douro, 5000-508 Vila Real, Portugal"}]},{"given":"Teresa","family":"Sousa","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7403-8998","authenticated-orcid":false,"given":"M\u00e1rcio","family":"Tavares","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Unidade Local de Sa\u00fade Gaia e Espinho, 4434-502 Vila Nova de Gaia, Portugal"}]},{"given":"Fernanda","family":"Trigo","sequence":"additional","affiliation":[{"name":"Hematology Department, Unidade Local de Sa\u00fade S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"given":"Adriana","family":"Roque","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Unidade Local de Sa\u00fade de Coimbra, 3004-561 Coimbra, Portugal"},{"name":"Physiology Institute, Faculdade de Medicina, Universidade de Coimbra, 1649-023 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7811-9509","authenticated-orcid":false,"given":"Rui","family":"Bergantim","sequence":"additional","affiliation":[{"name":"Hematology Department, Unidade Local de Sa\u00fade S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Cancer Drug Resistance Group, Institute of Molecular Pathology and Immunology (IPATIMUP), Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"i3S\u2014Institute for Research and Innovation in Health, Universidade do Porto, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3978-766X","authenticated-orcid":false,"given":"Cristina","family":"Jo\u00e3o","sequence":"additional","affiliation":[{"name":"Hemato-Oncology Unit, Funda\u00e7\u00e3o Champalimaud, 1400-038 Lisbon, Portugal"},{"name":"NOVA Medical School, NOVA University of Lisbon, 1169-056 Lisbon, Portugal"}]},{"name":"on behalf of the Portuguese Multiple Myeloma Group","sequence":"additional","affiliation":[]}],"member":"1968","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple Myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/10428194.2019.1695051","article-title":"Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma (MM)\u2014Possible Risks and Future Solutions: Retrospective and Prospective \u201cDeutsche Studiengruppe MM\u201d (DSMM) and \u201cEuropean Myeloma Network\u201d (EMN) Analysis","volume":"61","author":"Graziani","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e019758","DOI":"10.1136\/bmjopen-2017-019758","article-title":"Quantifying Intervals to Diagnosis in Myeloma: A Systematic Review and Meta-Analysis","volume":"8","author":"Koshiaris","year":"2018","journal-title":"BMJ Open"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zorlu, T., Kayer, M.A., Okumus, N., Ula\u015f, T., Dal, M.S., and Altuntas, F. (2025). Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma. Diagnostics, 15.","DOI":"10.20944\/preprints202505.0092.v1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3324\/haematol.2018.189159","article-title":"European Myeloma Network Recommendations on Tools for the Diagnosis and Monitoring of Multiple Myeloma: What to Use and When","volume":"103","author":"Caers","year":"2018","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on Multiparametric Flow Cytometry in Multiple Myeloma and Related Disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on Interphase FISH in Multiple Myeloma and Related Disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of Multiple Myeloma with High-Risk Cytogenetics: A Consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of Outcome in Newly Diagnosed Myeloma: A Meta-Analysis of the Molecular Profiles of 1905 Trial Patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"McPherson, R.A., and Massey, H.D. (2011). Laboratory Evaluation of Immunoglobulin Function and Humoral Immunity. Henry\u2019s Clinical Diagnosis and Management by Laboratory Methods, Elsevier.","DOI":"10.1016\/B978-1-4377-0974-2.00046-4"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cca.2011.03.007","article-title":"Free Immunoglobulin Light Chain: Its Biology and Implications in Diseases","volume":"412","author":"Nakano","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum Reference Intervals and Diagnostic Ranges for Free \u03ba and Free \u03bb Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrneph.2009.151","article-title":"Serum Free Light Chain Assessment in Monoclonal Gammopathy and Kidney Disease","volume":"5","author":"Hutchison","year":"2009","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1309\/6KT8N49BRNVVVBT1","article-title":"Performance Comparison of Capillary and Agarose Gel Electrophoresis for the Identification and Characterization of Monoclonal Immunoglobulins","volume":"129","author":"McCudden","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_17","first-page":"762","article-title":"Separation of Serum Proteins by Automated Capillary Zone Electrophoresis","volume":"41","author":"Bossuyt","year":"2003","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_18","first-page":"557","article-title":"Serum Protein Electrophoresis: Comparison of Capillary Zone Electrophoresis Capillarys (Sebia) and Agarose Gel Electrophoresis Hydrasys (Sebia)","volume":"61","author":"Lissoir","year":"2003","journal-title":"Ann. Biol. Clin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1515\/cclm-2015-0580","article-title":"Laboratory Testing Requirements for Diagnosis and Follow-up of Multiple Myeloma and Related Plasma Cell Dyscrasias","volume":"54","author":"Willrich","year":"2016","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1515\/cclm-2015-0862","article-title":"Challenges of Measuring Monoclonal Proteins in Serum","volume":"54","author":"Keren","year":"2016","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1515\/cclm-2019-1104","article-title":"An International Multi-Center Serum Protein Electrophoresis Accuracy and M-Protein Isotyping Study. Part I: Factors Impacting Limit of Quantitation of Serum Protein Electrophoresis","volume":"58","author":"Turner","year":"2020","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1373\/clinchem.2011.171314","article-title":"Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification: Implications for Monitoring Monoclonal Gammopathies","volume":"57","author":"Katzmann","year":"2011","journal-title":"Clin. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/cclm-2019-1105","article-title":"An International Multi-Center Serum Protein Electrophoresis Accuracy and M-Protein Isotyping Study. Part II: Limit of Detection and Follow-up of Patients with Small M-Proteins","volume":"58","author":"Jacobs","year":"2020","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/elps.200305820","article-title":"Interferences in Clinical Capillary Zone Electrophoresis of Serum Proteins","volume":"25","author":"Bossuyt","year":"2004","journal-title":"Electrophoresis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clinbiochem.2017.08.013","article-title":"Recognition and Management of Common, Rare, and Novel Serum Protein Electrophoresis and Immunofixation Interferences","volume":"51","author":"McCudden","year":"2018","journal-title":"Clin. Biochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.5858\/arpa.2017-0128-CP","article-title":"Screening and Diagnosis of Monoclonal Gammopathies: An International Survey of Laboratory Practice","volume":"142","author":"Genzen","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/jalm\/jfab067","article-title":"Immunotyping Provides Equivalent Results to Immunofixation in a Population with a High Prevalence of Monoclonal Gammopathies","volume":"6","author":"Thoren","year":"2021","journal-title":"J. Appl. Lab. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3324\/haematol.2013.084350","article-title":"Natural History and Prognostic Impact of Oligoclonal Humoral Response in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation: Long-Term Results from a Single Institution","volume":"98","author":"Tovar","year":"2013","journal-title":"Haematologica"},{"key":"ref_30","first-page":"113","article-title":"Significance of Abnormal Protein Bands in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation","volume":"30","author":"Hall","year":"2009","journal-title":"Clin. Biochem. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/0004563217710489","article-title":"Electrophoretic Patterns Post Daratumumab","volume":"55","author":"Sheldon","year":"2018","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/00045632211062080","article-title":"Case Report: Interference from Isatuximab on Serum Protein Electrophoresis Prevented Demonstration of Complete Remission in a Myeloma Patient","volume":"59","author":"Wheeler","year":"2022","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/leu.2015.290","article-title":"Clarification of the Definition of Complete Response in Multiple Myeloma","volume":"29","author":"Durie","year":"2015","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.V128.22.2063.2063","article-title":"Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test: Hydrashift 2\/4 Daratumumab","volume":"128","author":"Caillon","year":"2016","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jalm\/jfae028","article-title":"Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma","volume":"9","author":"Thoren","year":"2024","journal-title":"J. Appl. Lab. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.1158\/1078-0432.CCR-05-0486","article-title":"Serum Free Light Chain Analysis and Urine Immunofixation Electrophoresis in Patients with Multiple Myeloma","volume":"11","author":"Nowrousian","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ajh.25215","article-title":"Serum Free Light Chain Measurements to Reduce 24-h Urine Monitoring in Patients with Multiple Myeloma with Measurable Urine Monoclonal Protein","volume":"93","author":"Tschautscher","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41375-018-0339-y","article-title":"Responses in Multiple Myeloma Should Be Assigned According to Serum, Not Urine, Free Light Chain Measurements","volume":"33","author":"Dejoie","year":"2019","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2015.126797","article-title":"Comparison of Serum Free Light Chain and Urine Electrophoresis for the Detection of the Light Chain Component of Monoclonal Immunoglobulins in Light Chain and Intact Immunoglobulin Multiple Myeloma","volume":"101","author":"Dejoie","year":"2016","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening Panels for Detection of Monoclonal Gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of Multiple Myeloma-Related Renal Impairment: Recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2141.2007.06561.x","article-title":"Prognostic Value of Serum Free Light Chain Ratio at Diagnosis in Multiple Myeloma","volume":"137","author":"Kyrtsonis","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/bmt.2012.151","article-title":"Patterns of Relapse and Progression in Multiple Myeloma Patients after Auto-SCT: Implications for Patients\u2019 Monitoring after Transplantation","volume":"48","author":"Zamarin","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum Free Light Chain Ratio Is an Independent Risk Factor for Progression in Monoclonal Gammopathy of Undetermined Significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1515\/cclm-2017-0977","article-title":"Antigen Excess Detection by Automated Assays for Free Light Chains","volume":"59","author":"Bossuyt","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and Urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.12376","article-title":"Evaluation of the Serum Free Light Chain (SFLC) Analysis in Prediction of Response in Symptomatic Multiple Myeloma Patients: Rapid Profound Reduction in Involved FLC Predicts Achievement of VGPR","volume":"93","author":"Hansen","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hutchison, C.A., Plant, T., Drayson, M., Cockwell, P., Kountouri, M., Basnayake, K., Harding, S., Bradwell, A.R., and Mead, G. (2008). Serum Free Light Chain Measurement Aids the Diagnosis of Myeloma in Patients with Severe Renal Failure. BMC Nephrol., 9.","DOI":"10.1186\/1471-2369-9-11"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining New Reference Intervals for Serum Free Light Chains in Individuals with Chronic Kidney Disease: Results of the IStopMM Study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group Risk Stratification Model for Smoldering Multiple Myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Sabatino, R., Perrone, A., Cuomo, M., Liotti, S., Barchiesi, V., Cantile, M., and Cavalcanti, E. (2017). Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18040804"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e22243","DOI":"10.1002\/jcla.22243","article-title":"Serum Free Light Chain Quantitative Assays: Dilemma of a Biomarker","volume":"32","author":"Cigliana","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1515\/cclm-2023-0050","article-title":"Clinical Implication by Differential Analytical Performances of Serum Free Light Chain Quantitation Analysis Using Fully Automated Analyzers","volume":"61","author":"Yun","year":"2023","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group Guidelines for Serum-Free Light Chain Analysis in Multiple Myeloma and Related Disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1515\/cclm-2017-0817","article-title":"Analytical Validation of the Hevylite Assays for M-Protein Quantification","volume":"56","author":"Jacobs","year":"2018","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2009.123828","article-title":"Assessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin \u03ba\/\u03bb Ratios","volume":"55","author":"Bradwell","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1373\/clinchem.2014.231985","article-title":"Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy\/Light Chain Assays","volume":"61","author":"Katzmann","year":"2015","journal-title":"Clin. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.14026","article-title":"Levels of Uninvolved Immunoglobulins Predict Clinical Status and Progression--free Survival for Multiple Myeloma Patients","volume":"174","author":"Harutyunyan","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajh.24268","article-title":"Suppression of the Noninvolved Pair of the Myeloma Isotype Correlates with Poor Survival in Newly Diagnosed and Relapsed\/Refractory Patients with Myeloma","volume":"91","author":"Ludwig","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo, R., Puig, N., Algar\u00edn, M., Garc\u00eda de Veas Silva, J.L., Barbosa, N., Encinas, C., Hern\u00e1ndez, J.\u00c1., Alonso, R., Campos, M.L., and Rodr\u00edguez, T. (2021). The Current Role of the Heavy\/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach. Diagnostics, 11.","DOI":"10.3390\/diagnostics11112020"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.clml.2017.03.079","article-title":"Response Assignment Using Hevylite Correlates With Clinical Outcome in Multiple Myeloma","volume":"17","author":"Michallet","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary Plasma Cell Leukemia: Consensus Definition by the International Myeloma Working Group According to Peripheral Blood Plasma Cell Percentage","volume":"11","author":"Kyle","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Bain, B.J., Clark, D.M., and Wilkins, B.S. (2019). Bone Marrow Pathology, Wiley.","DOI":"10.1002\/9781119398929"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.morpho.2015.02.001","article-title":"Plasma Cell Morphology in Multiple Myeloma and Related Disorders","volume":"99","author":"Ribourtout","year":"2015","journal-title":"Morphologie"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1158\/1078-0432.CCR-16-0866","article-title":"New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma","volume":"22","author":"Landgren","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_70","first-page":"924","article-title":"Non-Secretory Myeloma: A Clinician\u2019s Guide","volume":"27","author":"Lonial","year":"2013","journal-title":"Oncology"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"The International Myeloma Working Group (2003). Criteria for the Classification of Monoclonal Gammopathies, Multiple Myeloma and Related Disorders: A Report of the International Myeloma Working Group. Br. J. Haematol., 121, 749\u2013757.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ajcp\/aqy034","article-title":"Is a 500-Cell Count Necessary for Bone Marrow Differentials?","volume":"150","author":"Abdulrahman","year":"2018","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo, R., S\u00e1nchez, M.J., G\u00f3mez-Rojas, S., Rodr\u00edguez-Barranco, M., Segura, G.P., Redondo-S\u00e1nchez, D., Carre\u00f1o-Tarragona, G., Nicol\u00e1s, A.R., Ruiz-Cabello, F., and Jim\u00e9nez, P. (2023). Cell Count Differentials by Cytomorphology and Next-Generation Flow Cytometry in Bone Marrow Aspirate: An Evidence-Based Approach. Diagnostics, 13.","DOI":"10.3390\/diagnostics13061071"},{"key":"ref_74","first-page":"333","article-title":"Morphologic Classification Is an Important Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib or Lenalidomide","volume":"50","author":"Takakuwa","year":"2020","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1751-553X.2008.01100.x","article-title":"ICSH Guidelines for the Standardization of Bone Marrow Specimens and Reports","volume":"30","author":"Lee","year":"2008","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.20512","article-title":"Utility of Flow Cytometry Immunophenotyping in Multiple Myeloma and Other Clonal Plasma Cell-related Disorders","volume":"78B","author":"Paiva","year":"2010","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New Criteria to Identify Risk of Progression in Monoclonal Gammopathy of Uncertain Significance and Smoldering Multiple Myeloma Based on Multiparameter Flow Cytometry Analysis of Bone Marrow Plasma Cells","volume":"110","author":"Vidriales","year":"2007","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","article-title":"Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA\/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy","volume":"26","author":"Mateo","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN Evidence-Based Guidelines for Diagnosis, Treatment and Follow-up of Patients with Multiple Myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow Antibody Panels for Standardized N-Dimensional Flow Cytometric Immunophenotyping of Normal, Reactive and Malignant Leukocytes","volume":"26","author":"Lhermitte","year":"2012","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood.V85.2.448.448","article-title":"A New Staging System for Multiple Myeloma Based on the Number of S-Phase Plasma Cells","volume":"85","author":"Moro","year":"1995","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"S\u0119dek, \u0141., Flores-Montero, J., van der Sluijs, A., Kulis, J., te Marvelde, J., Philipp\u00e9, J., B\u00f6ttcher, S., Bitter, M., Caetano, J., and van der Velden, V.H.J. (2022). Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels. Cancers, 14.","DOI":"10.3390\/cancers14030473"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2141.2006.06068.x","article-title":"Diverse Niches within Multiple Myeloma Bone Marrow Aspirates Affect Plasma Cell Enumeration","volume":"133","author":"Nadav","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A Large Meta-Analysis Establishes the Role of MRD Negativity in Long-Term Survival Outcomes in Patients with Multiple Myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE Meta-Analysis: Evaluating Minimal Residual Disease as an Intermediate Clinical End Point for Multiple Myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for Highly Sensitive and Standardized Detection of Minimal Residual Disease in Multiple Myeloma","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cyto.b.21228","article-title":"Consensus Guidelines on Plasma Cell Myeloma Minimal Residual Disease Analysis and Reporting","volume":"90","author":"Arroz","year":"2016","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Puig, N., Flores-Montero, J., Burgos, L., Cedena, M.-T., Cord\u00f3n, L., P\u00e9rez, J.-J., Sanoja-Flores, L., Manrique, I., Rodr\u00edguez-Otero, P., and Rosi\u00f1ol, L. (2021). Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13194924"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/leu.2010.160","article-title":"Automated Pattern-Guided Principal Component Analysis vs Expert-Based Immunophenotypic Classification of B-Cell Chronic Lymphoproliferative Disorders: A Step Forward in the Standardization of Clinical Immunophenotyping","volume":"24","author":"Costa","year":"2010","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/leu.2017.313","article-title":"Automated Database-Guided Expert-Supervised Orientation for Immunophenotypic Diagnosis and Classification of Acute Leukemia","volume":"32","author":"Lhermitte","year":"2018","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next Generation Flow for Minimally-Invasive Blood Characterization of MGUS and Multiple Myeloma at Diagnosis Based on Circulating Tumor Plasma Cells (CTPC)","volume":"8","author":"Paiva","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma","volume":"40","author":"Cedena","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Li, J., Wang, N., Tesfaluul, N., Gao, X., Liu, S., and Yue, B. (2017). Prognostic Value of Circulating Plasma Cells in Patients with Multiple Myeloma: A Meta-Analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181447"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/leu.2014.98","article-title":"Quantification of Clonal Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Implications for Redefining High-Risk Myeloma","volume":"28","author":"Gonsalves","year":"2014","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The Multiple Myelomas\u2014Current Concepts in Cytogenetic Classification and Therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-025-01286-w","article-title":"Guidelines for the Testing and Reporting of Cytogenetic Results for Risk Stratification of Multiple Myeloma: A Report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group","volume":"15","author":"Lu","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and Cytogenetics of Multiple Myeloma","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/bloodadvances.2019001275","article-title":"Metaphase Cytogenetics and Plasma Cell Proliferation Index for Risk Stratification in Newly Diagnosed Multiple Myeloma","volume":"4","author":"Mellors","year":"2020","journal-title":"Blood Adv."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2013-09-529800","article-title":"Robust Isolation of Malignant Plasma Cells in Multiple Myeloma","volume":"123","author":"Frigyesi","year":"2014","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group Molecular Classification of Multiple Myeloma: Spotlight Review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (MSMART): Consensus Statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus Recommendations for Risk Stratification in Multiple Myeloma: Report of the International Myeloma Workshop Consensus Panel 2","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma","volume":"43","author":"Davies","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/jclinpath-2015-203054","article-title":"Genomic Profiling of Myeloma: The Best Approach, a Comparison of Cytogenetics, FISH and Array-CGH of 112 Myeloma Cases","volume":"69","author":"Rack","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-022-00610-y","article-title":"Clonal and Subclonal TP53 Molecular Impairment Is Associated with Prognosis and Progression in Multiple Myeloma","volume":"12","author":"Martello","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic Significance of Copy-Number Alterations in Multiple Myeloma","volume":"27","author":"Li","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1200\/JCO.2008.19.1916","article-title":"Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma","volume":"27","author":"Anguiano","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Rosa-Rosa, J.M., Cuenca, I., Medina, A., V\u00e1zquez, I., S\u00e1nchez-delaCruz, A., Buenache, N., S\u00e1nchez, R., Jim\u00e9nez, C., Rosi\u00f1ol, L., and Guti\u00e9rrez, N.C. (2022). NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial. Cancers, 14.","DOI":"10.3390\/cancers14205169"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hon.3208","article-title":"Effect of MAPK Activation via Mutations in NRAS, KRAS and BRAF on Clinical Outcome in Newly Diagnosed Multiple Myeloma","volume":"41","author":"Perroud","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jmoldx.2020.02.005","article-title":"Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma","volume":"22","author":"Yao","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1002\/acg2.26","article-title":"Meeting Report: Advances in Minimal Residual Disease Testing in Multiple Myeloma 2018","volume":"2","author":"Landgren","year":"2019","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of Next-Generation Sequencing (NGS) and next-Generation Flow (NGF) for Minimal Residual Disease (MRD) Assessment in Multiple Myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_116","unstructured":"(2022). Medical laboratories\u2014Requirements for quality and competence (Standard No. ISO 15189:2022)."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1258\/acb.2011.011158","article-title":"Recommendations for Standardized Reporting of Protein Electrophoresis in Australia and New Zealand","volume":"49","author":"Tate","year":"2012","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/19\/7115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:33:39Z","timestamp":1760524419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/19\/7115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":117,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14197115"],"URL":"https:\/\/doi.org\/10.3390\/jcm14197115","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}